Design Therapeutics, Inc. (DSGN)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Pratik Shah Ph.D.
|
Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson | 790k | -- | 1970 |
|
Dr. Sean Jeffries Ph.D.
|
Chief Operating Officer | 698k | -- | 1980 |
|
Dr. Chris M. Storgard M.D.
|
Chief Medical Officer | 633.76k | -- | 1966 |
|
Dr. Aseem Z. Ansari Ph.D.
|
Co-Founder & Scientific Advisor | -- | -- | -- |
|
Ms. Julie D. Burgess CPA
|
Chief Accounting Officer | -- | -- | -- |
|
Mr. Doane Chilcoat Ph.D.
|
Chief Technology Officer | -- | -- | -- |
|
Mr. Mustapha Parekh
|
General Counsel | -- | -- | -- |
|
Dr. Tadimeti S. Rao Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
|
Mr. Jim Kerr
|
Chief of Manufacturing & Product Development | -- | -- | -- |
|
Dr. Chengzhi Zhang Ph.D.
|
Chief Chemist | -- | -- | -- |
Design Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 55
Description
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Corporate Governance
Upcoming Events
November 5, 2026 at 12:30 PM UTC
Design Therapeutics, Inc. Earnings Date
